Antidepressant Use During Pregnancy, Offspring Intellectual Disability Not Linked

This article originally appeared here.
Share this content:
The researchers aimed to identify a connection between maternal antidepressant use during pregnancy and intellectual disability in offspring.
The researchers aimed to identify a connection between maternal antidepressant use during pregnancy and intellectual disability in offspring.

There is no association between intellectual disability and maternal use of antidepressants during pregnancy, according to a study published in JAMA Psychiatry.1

Instead, the article, written by Alexander Viktorin, PhD, of Icahn School of Medicine at Mount Sinai in New York, New York, and colleagues attributed the association to a mechanism tied to other factors such as parental age and the mother's psychiatric disorders.

In this population-based cohort study, the researchers examined 179,007 children (51.5% male; mean age at follow up: 7.9±0.6) with complete parental information born between January 1, 2006 and December 31, 2007. Both maternal and paternal psychiatric diagnoses were also included to adjust for confounding variables.

The researchers aimed to identify a connection between maternal antidepressant use during pregnancy and intellectual disability in offspring, along with the role that parental mental illnesses may play (the cohort included 3982 children [2.2%] born to mothers with at least 2 dispensation periods that overlapped the pregnancy [single dispensations were analyzed separately because of uncertainty of exposure]).

The investigators found that 37 (0.9%) of children exposed to antidepressants had an intellectual disability, compared with 819 (0.5%) of children who were unexposed. Relative risk (RR) of intellectual disability for the full population sample was 1.33 (1.64 in a subsample analysis of mothers with depression). There was no clear relationship with disability in children with mothers who used non-selective serotonin reuptake inhibitor (SSRI) antidepressants (adjusted RR 0.81, 95% CI 0.33-2.00).

“This population-based cohort study was, to our knowledge, the first to directly assess the RR of diagnosed intellectual disability in children born to mothers treated with antidepressant medication during pregnancy,” the investigators said. “We observed a higher RR of intellectual disability among offspring born to mothers treated with antidepressants during pregnancy (0.9%of children affected) compared with offspring of mothers not treated with antidepressants during pregnancy of children affected before adjustment for confounding factors.”

“However,” they added, “with incremental adjustment for maternal and paternal confounding factors, this association was gradually attenuated to a statistically nonsignificant RR estimated at 1.33 (95% CI, 0.90-1.98),” they added. “Thus, the association between offspring [intellectual disability] and maternal antidepressant medication may, to a large extent, be explained by confounding by the covariates included and adjusted for in the current analyses.”

Follow @ClinicalPainAdv

Reference

  1. Viktorin A, Uher R, Kolevzon A, et al. Association of antidepressant medication use during pregnancy with intellectual disability in offspring. JAMA Psychiatry. Published online July 12, 2017. doi:10.1001/jamapsychiatry.2017.1727
You must be a registered member of Clinical Pain Advisor to post a comment.